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A B S T R A C T
Aim: A national atrial ﬁbrillation (AF) registry was conducted under the aegis of the Indian Heart Rhythm
Society (IHRS), to capture epidemiological data-type of AF, clinical presentation and comorbidities,
current treatment practices, and 1-year follow-up outcomes.
Methods: A total of 1537 patients were enrolled from 24 sites in India in the IHRS-AF registry from July
2011 to August 2012. Their baseline characteristics and follow-up data were recorded in case report
forms and subsequently analyzed.
Results: The average age of Indian AF patients was 54.7 years. There was a marginal female
preponderance – 51.5% females and 48.5% males. At baseline, 20.4% had paroxysmal AF; 33% had
persistent AF; 35.1% had permanent AF and 11% had ﬁrst AF episode. At one-year follow-up, 45.6%
patients had permanent AF.
Rheumatic valvular heart disease (RHD) was present in 47.6% of patients. Hypertension, heart failure,
coronary artery disease, and diabetes were seen in 31.4%, 18.7%, 16.2%, and 16.1%, respectively.
Rate control was the strategy used in 75.2% patients, digoxin and beta-blockers being the most
frequently prescribed rate-control drugs. Oral anticoagulation (OAC) drugs were used in 70% of patients.
The annual mortality was 6.5%, hospitalization 8%, and incidence of stroke 1%.
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third of the patients have persistent/permanent AF. At one-year follow-up, there is a signiﬁcant mortality
and morbidity in AF patients in India.
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Atrial ﬁbrillation (AF) is the most common sustained and
serious cardiac rhythm abnormality and is responsible for
substantial morbidity and mortality in the general population.1
AF is often seen in conjunction with cardiovascular disease,
hypertension, diabetes, and obesity, and also as an isolated
arrhythmia.1,2 Atrial ﬁbrillation patients have a higher mortality,
especially in presence of multiple comorbidities; it affects quality
of life and frequently leads to emergency room visits and
hospitalizations. Presently, the management of AF includes
assessment of thromboembolic risk and stroke prevention,
symptom management utilizing appropriate rate-control or
rhythm-control strategies, and treating associated diseases.1–4
There have been several studies evaluating the epidemiology of
AF in Western countries.5–8 In India, AF is a growing public health
problem in the context of the epidemiologic transition from
communicable to noncommunicable diseases. The effect of AF on
mortality and morbidity is likely to be substantial and increases the
economic burden. However, contemporary data on AF and its
outcomes are lacking from India. The use of anticoagulant and its
monitoring are major challenges for healthcare system in India due
to lack of accessibility to the monitoring test, lack of compliance by
patients, and interactions with diet and medicines. The IHRS
initiated a prospective AF registry, to characterize the epidemiologyFig. 1. Location of enrolling cent
Please cite this article in press as: Vora A, et al. Clinical presentation, 
Atrial Fibrillation (IHRS-AF) registry, Indian Heart J. (2016), http://dxand type of AF in India, its clinical presentation, management, and
outcomes.
2. Methods
2.1. Registry design
The IHRS-AF registry is an observational, multicentric, national
prospective study of men and women with AF in India. This
national registry was developed under the aegis of the IHRS and
was conducted across 24 sites, in 12 cities from India (Fig. 1). The
investigator in each of the center was an electrophysiologist or
practicing cardiologist and patients recruited were either from
outpatient clinic or admitted for atrial ﬁbrillation. The registry
started in July 2011 with a follow-up for each patient at 6 months
and 1 year from baseline evaluation. A total of 1537 patients were
enrolled from July 2011 to August 2012 and evaluated. To
minimize the risk of recruitment bias, the registry aimed for
consecutive patient recruitment at each site. At baseline, available
data were collected based on the following points: patient
demographics, medical history, type of AF, date and method of
diagnosis, symptoms, and treatment decisions. The following
additional information was collected during the baseline visit: past
treatments, changes in treatments, past INR values, dates of
monitoring, and past events. Follow-up data collection took placeers in the IHRS-AF registry.
management, and outcomes in the Indian Heart Rhythm Society-
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Table 1
Description of baseline characteristics of 1537 patients enrolled in the IHRS-AF
registry.
Baseline characteristics Values (measures
of central
tendency,
dispersion,
and range)
Age, years
Mean  SD, min–max 54.7  15.9, 15–96 years
Median, 25th–75th 55, 42–67 years
Gender
Men 746 (48.5%)
Females 791 (51.5%)
Medical history, N (%)
Known history of AF 904 (58.8)
Rheumatic valvular heart disease 732 (47.6)
Hypertension 482 (31.4)
Heart failure 288 (18.7)
Diabetes mellitus 248 (16.1)
Other 163 (10.6)
Stroke/transient ischemic attack/thromboembolism 141 (9.17)
Hyperlipidemia 131 (8.52)
Cardiomyopathy 126 (8.19)
Thyroid disease 120 (7.8)
COPD/lung disease 120 (7.8)
Old Infarction 83 (5.4)
Nonrheumatic valvular heart disease 83 (5.4)
Renal failure 70 (4.55)
Sick sinus syndrome 68 (4.42)
Angina 60 (3.9)
Bleeding 49 (3.2)
Atrial septal defect/congenital heart disease 28 (1.8)
Obstructive sleep apnea 31 (2.01)
Family has AF history 26 (1.7)
Peripheral vascular disease 18 (1.1)
Procedures, N (%)
Valve replacement surgery 187 (12.2)
Previous percutaneous coronary
intervention/coronary artery bypass grafting
106 (6.9)
Medications, N (%)
Aspirin 354 (23.0)
Clopidogrel 202 (13.1)
Other antiplatelets 9 (0.6)
Combination of antiplatelets 31 (2.02)
Warfarin 637 (41.4)
Acenocoumarin 439 (28.6)
Other oral anticoagulants 60 (3.9)
CHADS2 score, N (%)
(excluding patients with rheumatic
valvular heart diseases)
787 (100)
0 91 (11.6)
1 157 (19.9)
2 167 (21.2)
3 372 (47.3)
HAS-BLED score, N (%)
0 259 (17.1)
1 505 (33.3)
2 286 (18.9)
3 466 (30.7)
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the aim of documenting all clinical events and treatment. Outcome
data included hospitalization, stroke, interventions, bleeding
complications, and death. Bleeding complication was recorded
as major (if hospitalization or blood transfusion was necessary) or
minor (if only adjustment of anticoagulant dose was necessary). In
case of no follow-up at scheduled time, a telephonic reason for no
follow-up and outcome event if any was recorded.
Independent ethics committee and hospital-based institutional
review board approvals were obtained, as necessary, for the
registry protocol. All patients were provided written informed
consent to participate. As an observational registry, no speciﬁc
treatments, tests, or procedures were mandated or withheld from
the patients, and patients were free to withdraw from the registry
at any time. Data were summarized in subgroups using measures
of central tendency and dispersion, number of patients for
continuous data, and as count and percentage for categorical data.
3. Results
The IHRS-AF registry enrolled 1537 patients with AF across
24 sites in India. These patients were followed with a 6-month and
12-month follow-up visit. Of the 1537 patients enrolled at
baseline, 1399 patients (91.02%) were assessed during their 6-
monthly, follow-up visit and 1375 patients (89.45%) were assessed
during their 12-monthly, follow-up visit. The baseline character-
istics of these AF patients are detailed in Table 1. The mean age of
the entire cohort of AF patients was 54.7  15.9 years (range 18–96
years). There was a marginal female preponderance – 51.5% females
and 48.5% males. Rheumatic heart disease (RHD) was present in 47.6%
of patients. Hypertension was noted in 31.4%; heart failure in 18.7%;
diabetes in 16.1% and coronary artery disease in 16.2% patients.
At baseline visit, 20.4% of the patients were diagnosed to have
paroxysmal AF while 33.0% and 35.1% had persistent and
permanent AF, respectively. 11% had presented with ﬁrst episode
of AF. At one-year follow-up, 45.6% patients were in permanent AF;
10.5% and 20.3% continued to have paroxysmal and persistent AF,
respectively and 22.6% patients had no further AF (Fig. 2).
In this IHRS-AF registry, rate-control strategy was adopted in
75.25% of the patients. Rate control as deﬁned by a resting heart
rate <90 bpm was achieved in 66% of the patients at 1-year follow-
up. The antiarrhythmic drugs used were digoxin (27%), beta-
blockers (21%), calcium channel blockers (15%), amiodarone (17%),
and sotalol (1%). Of the patients assigned to rate-control drugs,
approximately 3% switched to rhythm-control strategy on follow-
up and approximately 20% of the patients assigned to rhythm
control switched to rate control on follow-up. At one-year follow-
up, rate-control strategy was assigned to 79% patients.
The stroke prevention strategy was oral anticoagulation
(warfarin or acenocoumarin) in 70% patients and antiplatelets
(aspirin or clopidogrel) in the remaining 30% patients. Of the RHD
patients, 83% received oral anticoagulants. The CHADS2 scoring in
the non-RHD patients was 0 in 11.6%; 1 in 19.9%; 2 in 21.2% and
more than 3 in 47.3%. The bleeding risk as evaluated by the HAS-
BLED score was 0 in 17.1%; 1 in 33.3%; 2 in 18.9% and more than 3 in
30.7% patients. In the non-RHD AF patients, 53.5% were prescribed
oral anticoagulants. The proportion of patients on oral antic-
oagulants was comparable to patients with paroxysmal, persistent
and permanent AF.
At one-year follow-up, 16 (1.03%) patients had stroke. Of these
16 patients, 15 were on oral anticoagulants with a mean INR of
1.85. Eight patients had ischemic stroke and 6 patients had
hemorrhagic stroke (type of stroke undetermined in 2 patients).
Four patients died of stroke (25% mortality).
In the one-year follow-up, 43 (2.70%) patients had bleeding
complications. 40 patients were on oral anticoagulants with aPlease cite this article in press as: Vora A, et al. Clinical presentation, 
Atrial Fibrillation (IHRS-AF) registry, Indian Heart J. (2016), http://dxmean INR of 1.71. Thirty patients had minor bleeding complica-
tions and 13 patients (0.85%) had major bleeding complications, i.e.
requiring hospitalization or blood transfusion.
The all-cause mortality rate was 6.5% (100 patients) at one-year
follow-up. The common causes of death were heart failure (35%),
myocardial infarction (14%), sudden cardiac death (12%), stroke
(4%), and noncardiac causes (12%) (Table 2). The rate of
hospitalization was 8% (with 123 hospitalization events in
109 patients) during the 1-year follow-up period. The causes of
hospitalization (Table 3) were stroke (13%), angina needing
coronary interventions (13%), symptomatic heart failure (10%),management, and outcomes in the Indian Heart Rhythm Society-
.doi.org/10.1016/j.ihj.2016.06.006
Fig. 2. Difference in each atrial ﬁbrillation type from baseline to 12-month follow-up visit.
Table 3
Reasons for 123 hospitalizations in 109 patients who were hospitalized during the
1-year follow-up period in the IHRS-AF registry.
Reason for hospitalization Number of hospitalizations
Heart failure 12
Fast VR 10
Angina and coronary interventions 16
Valvular interventions 12
Cardioversion 5
Ventricular arrhythmias 4
Stroke 16
Digoxin toxicity 1
Noncardiovascular reasons 47
Total 123
Table 2
Causes of death identiﬁed in the 100 patients who died during the 1-year follow-up
period in the IHRS-AF registry.
Identiﬁed cause of death Number of deaths
Heart failure 35
Myocardial infarction 14
Sudden cardiac death 14
Stroke 5
Noncardiac 12
Noncardiac causes:
Respiratory infection/disease – 5
Accident/suicide – 3
Renal failure – 2
Cancer – 2
Unknown 20
Total 100
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cardioversion (4%) (Table 3).
4. Discussion
The IHRS-AF registry is the largest evaluation of the clinical
presentation, management, and outcomes in patients with AF in
India. The IHRS-AF registry reveals that the Indian AF patients are
more than a decade younger than the AF patients in the western
world.9 Also, the proportion of AF patients with RHD was
signiﬁcantly higher in India (47.6%).10 There was not a signiﬁcantPlease cite this article in press as: Vora A, et al. Clinical presentation, 
Atrial Fibrillation (IHRS-AF) registry, Indian Heart J. (2016), http://dxdifference between the mean age of patients without and with
RHD (55.6 vs 53.6 years). The relatively younger age of Indian AF
patients is therefore not primarily determined by RHD. In fact, it
appears that a higher prevalence of hypertension, diabetes, and
coronary artery disease in the young in India11 is responsible/
associated with younger AF patients.
Two-thirds of Indian AF patients were either persistent or
permanent type of AF. This trend is unlike the western AF
population. Chronicity of AF in India patients seems related to the
higher prevalence of RHD. Over one-year follow-up, more patients
progressed from paroxysmal and persistent variety to permanent
AF (46%).
The predominant strategy of rate control for AF is understand-
able with a higher prevalence of RHD and more persistent/
permanent AF. At one year, almost 80% patients were assigned to
rate control. Resting heart rate of <90 bpm was achievable in only
two-thirds of the patients at one-year follow-up. Nonavailability of
class IC antiarrhythmic drugs like propafenone and ﬂecainide
during the study period (2011–2012) led to predominant use of
amiodarone as the rhythm-control drug.
The overall use of anticoagulants was 70%, reasonable when
compared to other nations. In RHD patients, the utilization of
anticoagulants was better at 83%. Vast majority of the non-RHD
patients had a high CHADS2 score (2 or more in 68.5%). There was a
tendency to under anticoagulate, as the average INR of the entire
cohort over one year was 1.8.
The stroke rate was 1%/year and this is comparable to the
reported literature, especially with higher RHD patients and
CHADS2 score. Stroke was the reason for hospitalization in 13%
patients. Eight patients had ischemic stroke and 6 had hemorrhagic
stroke. Four of the 16 stroke patients died, a mortality of 25%.
The major bleeds (requiring hospitalization and or blood
transfusion) were less than 1%; however, all bleeding complica-
tions were seen in 43 patients (2.7%). Bleeding complications is
comparable to literature reports. It was however surprising to
observe that the average INR in these patients who had bleeding
was low at 1.71.
The annual mortality of AF was 6.5%. This is similar to what was
noted in the European AF registry12; however, their patients were
almost two decades older than in IHRS-AF registry. The higher
mortality in IHRS-AF was predominantly due to heart failure,
myocardial infarction, sudden death, and stroke. Rheumatic heart
disease and comorbidities such as hypertension, coronary artery
disease, and diabetes probably result in higher mortality in AF.management, and outcomes in the Indian Heart Rhythm Society-
.doi.org/10.1016/j.ihj.2016.06.006
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recruited from tertiary referral centers.
The annual hospitalization was 8%. Cardioversion and valvular
interventions are legitimate reasons for hospitalization in the hope
of improving symptoms and translating to better long-term
outcome and these constituted 14%. However, heart failure and
rapid ventricular rates accounted for 22% of hospitalizations.
Interestingly, angina and coronary interventions were necessary in
13% of the patients requiring hospitalizations. This relatively
higher incidence is likely because of higher prevalence of
hypertension and diabetes in the Indian AF patients.
4.1. Study limitations
There is likely to be a selection bias in view of recruitment of
patients predominantly from tertiary referral centers, managed by
electrophysiologists or interventional cardiologist. The community
incidence and prevalence of AF is lacking. A segregation of patients
from public and private institutes might further help deﬁne the
type of AF burden and guide management strategies.
5. Conclusion
In India, AF patients are younger, and RHD is widely prevalent
necessitating speciﬁc treatment with respect to anticoagulation,
rate control, and valvular interventions. The overall mortality and
hospitalization are higher, primarily due to heart failure and
stroke, which needs to be prevented and promptly treated.
Measures to improve the use and monitoring of oral antic-
oagulation will favorably impact stroke, which is a major cause of
morbidity and mortality. The current availability of class IC
antiarrhythmic drugs and novel oral anticoagulants along with
radiofrequency ablation in selected patients may further improve
outcomes in AF patients.Please cite this article in press as: Vora A, et al. Clinical presentation, 
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